Avacta Group

Activities: Research & Development Analysis Pharmaceutical

Trending Articles

  1. Counteracting counterfeits in the pharmaceutical supply chain Sreedhar Patnala, General Manager at Systech, discusses the comprehensive benefits of embracing traceability
  2. Catalent Boston adds to oral spray drying capacity to support late-stage clinical trials and commercialisation Catalent, the leading provider of oral drug development solutions, bioavailability enhancing technologies and flexible manufacturing, has completed a series of upgrades to its...
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  4. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human...
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Industrial data mastery: navigating the 2025 landscape As industrial manufacturers contend with the ever-increasing volume and variety of operational data, the year ahead promises both complexity and opportunity

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

Related Content

Research & Development

Avacta achieves milestone in AffyXell joint venture

The second milestone will result in an increase in Avacta’s shareholding in AffyXell, which currently stands at 19%
Research & Development

AffyXell expands partnership with GenScript ProBio

As part of the strategic alliance, GenScript has committed to take an equity position in AffyXell at a future funding round
Finance

Avacta appoints Non-Executive Director to board

Christina Coughlin previously served as CMO to Rubius Therapeutics, where she led the clinical development, translational medicine and regulatory efforts for the company
Analysis

Avacta provides update on its antigen test for Omicron

The company has taken the decision to pause sales of the AffiDX antigen test while it replaces the antibody in the product to ensure its performance with the Omicron variant matches that of the previous mutations
Finance

Astrea Bioseparations invests in infrastructure in UK and Singapore

The company has expanded its R&D facility in Cambridge, UK, and registered a branch office in Singapore
Finance

Avacta appoints Chief Scientific Officer of therapeutics division

Dr Alastair Smith, CEO of Avacta Group, commented: “We are delighted to have Fiona McLaughlin join us as Chief Scientific Officer of our therapeutics division
Finance

Avacta appoints Dr Mark Goldberg as Non-Executive Director

Goldberg currently serves on the boards of directors of ImmunoGen, Idera Pharmaceuticals, GlycoMimetics, Walden Biosciences, and Blueprint Medicines
Subscribe now